Allogene Therapeutics financials
$1.62−0.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $22.0K | $95.0K | $156.0K | $114.1M | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $22.0K | $95.0K | $156.0K | $114.1M | $0.00 | $0.00 | — |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating income | -$209.3M | -$273.2M | -$327.7M | -$335.5M | -$180.2M | -$258.2M | -$202.3M | -$192.8M |
| Net income | -$190.9M | -$257.6M | -$327.3M | -$340.4M | -$182.1M | -$316.4M | -$184.6M | -$211.5M |
| Net margin | — | −1170863.6% | −344489.5% | −218214.1% | −159.6% | — | — | — |
| Diluted EPS | $-0.87 | $-1.32 | $-2.09 | $-2.38 | $-1.34 | $-2.63 | $-1.83 | $-7.31 |
| EBITDA | -$194.6M | -$243.8M | -$300.3M | -$321.2M | -$169.7M | -$250.7M | -$197.2M | -$191.3M |
| Operating cash flow | -$149.2M | -$200.3M | -$237.7M | -$220.5M | -$184.8M | -$115.1M | -$137.3M | -$44.7M |
| Free cash flow | -$149.6M | -$201.0M | -$239.2M | -$225.7M | -$206.3M | -$181.1M | -$188.1M | -$47.9M |
| Diluted shares | 220.6M | 194.8M | 156.9M | 143.1M | 135.8M | 120.4M | 101.1M | 28.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $51.7M | $75.2M | $83.2M | $61.9M | $173.3M | $183.4M |
| Short-term investments | $198.5M | $217.3M | $365.5M | $455.4M | $284.0M | $644.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $415.9M | $548.7M | $642.8M | $821.6M | $1.05B | $1.23B |
| Total liabilities | $123.4M | $126.5M | $130.6M | $154.7M | $125.6M | $148.2M |
| Shareholders' equity | $292.5M | $422.2M | $512.2M | $666.9M | $925.2M | $1.08B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology